Giant cell (temporal) arteritis: An overview and update

Survey of Ophthalmology

Volumn 50, Issue 5, 2005, Pages 415-428

  Rahman, Waheeda ^a,c   Rahman, Farooq Z ^b  

^a Department of Ophthalmology ^*  (United Kingdom)

^b WHITTINGTON HOSPITAL   (United Kingdom)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Blindness; Giant cell arteritis; Sudden visual loss; Temporal arteritis; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; HISTAMINE H2 RECEPTOR ANTAGONIST; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; METHYLPREDNISOLONE; PROTON PUMP INHIBITOR; VITAMIN D;

ABDOMINAL PAIN; AMYLOIDOSIS; AVASCULAR NECROSIS; BLOOD RHEOLOGY; BLOOD VESSEL BIOPSY; BONE PAIN; CELLULAR IMMUNITY; CERVICAL SPONDYLOSIS; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CORTICOSTEROID THERAPY; CUSHING SYNDROME; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE TIME EFFECT RELATION; DRUG MEGADOSE; DUODENUM ULCER; DYSPEPSIA; EAR DISEASE; EARLY DIAGNOSIS; EUPHORIA; EYE DISEASE; FEMUR HEAD; FLUORESCENCE ANGIOGRAPHY; GIANT CELL ARTERITIS; GLAUCOMA; HUMAN; HUMORAL IMMUNITY; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INDIGESTION; INFECTION; LABORATORY TEST; LONG TERM CARE; MAINTENANCE DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MUSCLE ATROPHY; MYALGIA; OPHTHALMOSCOPY; OSTEOPOROSIS; PEPTIC ULCER; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; REVIEW; SINUS NODE DISEASE; SPONDYLOARTHROPATHY; STOMACH PROTECTION; SYSTEMIC DISEASE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC VASCULITIS; TEMPORAL ARTERY; TOOTH DISEASE; TREATMENT PLANNING; TRIGEMINUS NEURALGIA; VISUAL IMPAIRMENT;

BIOPSY; DIAGNOSIS, DIFFERENTIAL; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TEMPORAL ARTERIES; TEMPORAL ARTERITIS;

EID: 24044527580     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2005.06.011     Document Type: Review

References (137)

1. A.A. Achkar, J.T. Lie, and G.G. Hunder How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 120 1994 987 992
2. P.D. Aiello, J.C. Trautmann, and T.J. McPhee Visual prognosis in giant cell arteritis Ophthalmology 100 1993 550 555
3. D.M. Albert, S.S. Searl, and J.L. Craft Histologic and ultrastructural characteristics of temporal arteritis. The value of the temporal artery biopsy Ophthalmology 89 1982 1111 1126
4. H.J. Anders, T. Sigl, and A. Sander Gadolinium contrast magnetic resonance imaging of the temporal artery in giant cell arteritis J Rheumatol 26 1999 2287 2288
5. R. Andersson, B.E. Malmvall, and B.A. Bengtsson Long-term corticosteroid treatment in giant cell arteritis Acta Med Scand 220 1986 465 469
6. M. Ashton-Key, and P.J. Gallagher Surgical pathology of cranial arteritis and polymyalgia rheumatica Baillieres Clin Rheumatol 5 1991 387 404
7. O. Baldursson, K. Steinsson, and J. Björnsson Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis Arthritis Rheum 37 1994 1007 1012
8. B.A. Bengtsson, and B.E. Malmvall The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications Arthritis Rheum 24 1981 899 904
9. M.T. Bhatti, and M.H. Goldstein Facial nerve injury following superficial temporal artery biopsy Dermatol Surg 27 2001 15 17
10. M.T. Bhatti, and H. Tabandeh Giant cell arteritis: diagnosis and management Curr Opin Ophthalmol 12 2001 393 399
11. S. Blumberg, D.F. Giansiracusa, and W.P. Docken Recurrence of temporal arteritis. Clinical recurrence nine years after initial illness JAMA 244 1980 1713
12. P. Boesen, and S.F. Sørensen Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county. A prospective investigation, 1982-1985 Arthritis Rheum 30 1987 294 299
13. A. Brack, A. Geisler, and V. Martinez-Taboada Giant cell vasculitis is a T cell dependent disease J Mol Med 81 1997 29 55
14. K.T. Calamia, and G.G. Hunder Clinical manifestations of giant-cell (temporal) arteritis Clin Rheum Dis 6 1980 389 403
15. F. Cantini, L. Niccoli, and C. Salvarani Treatment of longstanding active giant cell arteritis with infliximab: report of four cases Arthritis Rheum 44 2001 2933 2935
16. D. Caplanne, J. LePark, and J. Alexandre Interleukin-6 in clinical relapse of polymyalgia rheumatica and giant cell arteritis Ann Rheum Dis 55 1996 403 404
17. R.J. Caselli Giant cell (temporal) arteritis: a treatable cause of multi-infarct dementia Neurology 40 1990 753 755
18. R.J. Caselli, G.G. Hunder, and J.P. Whisnant Neurologic disease in biopsy-proven giant cell (temporal) arteritis Neurology 38 1988 352 359
19. J. Chess, D.M. Albert, and A.K. Bhan Serologic and immunopathologic findings in temporal arteritis Am J Ophthalmol 96 1983 283 289
20. P. Chevalet, J.H. Barrier, and P. Pottier A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients J Rheumatol 27 2000 1484 1491
21. M.C. Cid, C. Font, and J. Oristrell Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis Arthritis Rheum 41 1998 26 32
22. W.T. Cornblath, and E.R. Eggenberger Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone Ophthalmology 104 1997 854 858
23. J.F. Cullen Temporal arteritis. Occurrence of ocular complications 7 years after diagnosis Br J Ophthalmol 56 1972 584 588
24. A. Dababneh, M.A. Gonzalez-Gay, and C. Garcia-Porrua Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association J Rheumatol 25 1998 2140 2145
25. G.D. Desmet, D.C. Knockaert, and H.J. Bobbaers Temporal arteritis: the silent presentation and delay in diagnosis J Intern Med 227 1990 237 240
26. W. Dummer, D. Zillikens, and A. Schulz Scalp necrosis in temporal (giant cell) arteritis:implications for the dermatologic surgeon Clin Exp Dermatol 21 1996 154 158
27. T. Dwolatsky, M. Sonnenblick, and G. Nesher Giant cell arteritis and polymyalgia rheumatica: clues to early diagnosis Geriatrics 52 1997 38 40
28. L.R. Espinoza, L.J. Jara, and L.H. Silveira Anticardiolipin antibodies in polymyalgia rheumatica-giant cell arteritis: association with severe vascular complications Am J Med 90 1991 474 478
29. J.M. Evans, and G.G. Hunder Polymyalgia rheumatica and giant cell arteritis Rheum Dis Clin North Am 26 2000 493 515
30. L. Fernandez-Herlihy Duration of corticosteroid therapy in giant cell arteritis J Rheumatol 7 1980 361 364
31. G.F. Ferraccioli, E. Di Poi, and R. Damato Steroid sparing therapeutic approaches to polymyalgia rheumatica-giant cell arteritis. State of the art and perspectives Clin Exp Rheumatol 18 2000 S58 S60
32. P. Fietta, P. Manganelli, and A. Zanetti Familial giant cell arteritis and polymyalgia rheumatica: aggregation in 2 families J Rheumatol 29 2002 1551 1555
33. R. Finlay Oral prednisolone 40 mg daily is not adequate for temporal arteritis once vision is affected BMJ 315 1997 549
34. C. Font, M.C. Cid, and B. Coll-Vinent Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis Br J Rheumatol 36 1997 251 254
35. R. Foroozan, H. Danesh-Meyer, and P.J. Savino Thrombocytosis in patients with biopsy-proven giant cell arteritis Ophthalmology 109 2002 1267 1271
36. R. Foroozan, V.A. Deramo, and L.M. Buono Recovery of visual function in patients with biopsy-proven giant cell arteritis Ophthalmology 110 2003 539 542
37. O. Fruchter, H. Ben-Ami, and D. Schapira Giant cell arteritis complicated by spinal cord infarction: a therapeutic dilemma J Rheumatol 29 2002 1556 1558
38. S.E. Gabriel, W.M. O'Fallon, and A.A. Achkar The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis J Rheumatol 22 1995 93 96
39. F.D. Ghanchi, C. Weir, and J. Dudgeon Facial swelling in giant cell (temporal) arteritis Eye 10 Pt 6 1996 747 749
40. F.D. Ghanchi, T.H. Williamson, and C.S. Lim Colour Doppler imaging in giant cell (temporal) arteritis: serial examination and comparison with non-arteritic anterior ischaemic optic neuropathy Eye 10 Pt 4 1996 459 464
41. P. Gonzalez-Alegre, A.D. Ruiz-Lopez, and M. Abarca-Costalago Increment of the platelet count in temporal arteritis: response to therapy and ischemic complications Eur Neurol 45 2001 43 45
42. M.A. Gonzalez-Gay, C. Garcia-Porrua, and J. Llorca Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy Semin Arthritis Rheum 30 2001 249 256
43. M.A. González-Gay, R. Blanco, and V. Abraira Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality J Rheumatol 24 1997 2171 2176
44. M.A. González-Gay, C. García-Porrúa, and J. Llorca Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients Medicine (Baltimore) 79 2000 283 292
45. J.J. Goronzy, and C.M. Weyand Cytokines in giant-cell arteritis Cleve Clin J Med 69 Suppl 2 2002 SII91 SII94
46. E. Graham, A. Holland, and A. Avery Prognosis in giant-cell arteritis Br Med J (Clin Res Ed) 282 1981 269 271
47. J.T. Gran, G. Myklebust, and T. Wilsgaard Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls Rheumatology (Oxford) 40 2001 1238 1242
48. E. Hachulla, V. Boivin, and U. Pasturel-Michon Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis Clin Exp Rheumatol 19 2001 171 176
49. H.J. Haga, G.E. Eide, and J. Brun Cancer in association with polymyalgia rheumatica and temporal arteritis J Rheumatol 20 1993 1335 1339
50. E.C. Hagen, M.R. Daha, and J. Hermans Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization Kidney Int 53 1998 743 753
51. S. Harada, F. Mitsunobu, and F. Kodama Giant cell arteritis associated with rheumatoid arthritis monitored by magnetic resonance angiography Intern Med 38 1999 675 678
52. S.S. Hayreh Steroid therapy for visual loss in patients with giant-cell arteritis Lancet 355 2000 1572 1573
53. S.S. Hayreh Factors influencing blood flow in the optic nerve head J Glaucoma 6 1997 412 425
54. S.S. Hayreh Acute ischemic disorders of the optic nerve: Pathogenesis, clinical manifestations and management Ophthalmol Clin North Am 9 1996 407 442
55. S.S. Hayreh Ophthalmic features of giant cell arteritis Baillieres Clin Rheumatol 5 1991 431 459
56. S.S. Hayreh Anterior ischaemic optic neuropathy. Differentiation of arteritic from non-arteritic type and its management Eye 4 Pt 1 1990 25 41
57. S.S. Hayreh Posterior ischemic optic neuropathy Ophthalmologica 182 1981 29 41
58. S.S. Hayreh Anterior Ischemic Optic Neuropathy 1975 Springer New York pp 14-22, 27-8, 113-5
59. S.S. Hayreh, P.A. Podhajsky, and R. Raman Giant cell arteritis: validity and reliability of various diagnostic criteria Am J Ophthalmol 123 1997 285 296
60. S.S. Hayreh, P.A. Podhajsky, and B. Zimmerman Ocular manifestations of giant cell arteritis Am J Ophthalmol 125 1998 509 520
61. S.S. Hayreh, P.A. Podhajsky, and B. Zimmerman Occult giant cell arteritis: ocular manifestations Am J Ophthalmol 125 1998 521 526
62. S.S. Hayreh, and B. Zimmerman Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy Ophthalmology 110 2003 1204 1215
63. S.S. Hayreh, and B. Zimmerman Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies Ophthalmologica 217 2003 239 259
64. S.S. Hayreh, B. Zimmerman, and R.H. Kardon Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature Acta Ophthalmol Scand 80 2002 355 367
65. B. Hazleman Laboratory investigations useful in the evaluation of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) Clin Exp Rheumatol 18 2001 S29 S31
66. L.A. Healey, and K.R. Wilske Presentation of occult giant cell arteritis Arthritis Rheum 23 1980 641 643
67. J. Hernández-Rodríguez, A. García-Martínez, and J. Casademont A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis Arthritis Rheum 47 2002 29 35
68. J. Hernández-Rodríguez, M. Segarra, and C. Vilardell Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism Circulation 107 2003 2428 2434
69. G.S. Hoffman, M.C. Cid, and D.B. Hellmann A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis Arthritis Rheum 46 2002 1309 1318
70. Homik J, Cranney A, Shea B,, et al. Bisphosphonates for steroid induced osteoporosis.(Cochrane Review). In: The Cochrane Library, Issue 2, 2001. Oxford: Update Software
71. B.T. Horton, T.B. Magath, and G.E. Brown An undescribed form of arthritis of the temporal vessels Proc Mayo Clin 7 1932 700 701
72. G.G. Hunder Giant cell arteritis and polymyalgia rheumatica Med Clin North Am 81 1997 195 219
73. G.G. Hunder, D.A. Bloch, and B.A. Michel The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis Arthritis Rheum 33 1990 1122 1128
74. G.G. Hunder, and C.M. Weyand Sonography in giant-cell arteritis N Engl J Med 337 1997 1385 1386
75. J. Hutchinson On a peculiar form of thrombotic arteritis of the aged which is sometimes productive of gangrene Arch Surg 1 1890 323 329
76. J.G. Jones Clinical features of giant cell arteritis B.L. Hazelman B.-A. Bengtsson Bailliere's clinical Rheumatology 1991 Bailliere Tindall London 414
77. J.A. Jover, C. Hernández-García, and I.C. Morado Combined treatment of giant-cell arteritis with methotrexate and prednisolone. a randomized, double-blind, placebo-controlled trial Ann Intern Med 134 2001 106 114
78. J.L. Keltner Giant-cell arteritis. Signs and symptoms Ophthalmology 89 1982 1101 1110
79. S. Knecht, H. Henningsen, and E.W. Rauterberg Immunohistology of temporal arteritis: phenotyping of infiltrating cells and deposits of complement components J Neurol 238 1991 181 182
80. V. Kyle Treatment of polymyalgia rheumatica/giant cell arteritis Baillieres Clin Rheumatol 5 1991 485 491
81. V. Kyle, and B.L. Hazelman Stopping steroids in polymyalgia rheumatica and giant cell arteritis BMJ 300 1990 344 345
82. V. Kyle, and B.L. Hazleman The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment Ann Rheum Dis 52 1993 847 850
83. N.S. Lincoff, P.D. Erlich, and L.S. Brass Thrombocytosis in temporal arteritis rising platelet counts: a red flag for giant cell arteritis J Neuroophthalmol 20 2000 67 72
84. E. Liozon, F. Herrmann, and K. Ly Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients Am J Med 111 2001 211 217
85. E. Liozon, P. Roblot, and D. Paire Anticardiolipin antibody levels predict flares and relapses in patients with giant-cell (temporal) arteritis. A longitudinal study of 58 biopsy-proven cases Rheumatology (Oxford) 39 2000 1089 1094
86. G.T. Liu, J.S. Glaser, and N.J. Schatz Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision Ophthalmology 101 1994 1779 1785
87. H.G. Mack, J. O'Day, and J.N. Currie Delayed choroidal perfusion in giant cell arteritis J Clin Neuroophthalmol 11 1991 221 227
88. V. Martinez-Taboada, N.N. Hunder, and G.G. Hunder Recognition of tissue residing antigen by T cells in vasculitic lesions of giant cell arteritis J Mol Med 74 1996 695 703
89. E.L. Matteson, K.N. Gold, and D.A. Bloch Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort Am J Med 100 1996 193 196
90. A. Miller, M. Green, and D. Robinson Simple rule for calculating normal erythrocyte sedimentation rate Br Med J (Clin Res Ed) 286 1983 266
91. T.R. Mizen Giant cell arteritis: diagnostic and therapeutic considerations Ophthal Clin North Am 4 1991 547 556
92. H. Murgatroyd, and A. Milne Positive temporal artery biopsy in a patient on therapeutic doses of steroids for six years Eye 15 2001 250 251
93. G. Myklebust, T. Wilsgaard, and B.K. Jacobsen No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls J Rheumatol 29 2002 2143 2147
94. A.B. Myles, T. Perera, and M.G. Ridley Prevention of blindness in giant cell arteritis by corticosteroid treatment Br J Rheumatol 31 1992 103 105
95. M. Navarro, R. Cervera, and J. Font Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance Lupus 6 1997 521 526
96. G. Nesher, A. Rubinow, and M. Sonnenblick Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study Clin Exp Rheumatol 15 1997 303 306
97. G. Nesher, M. Sonnenblick, and Y. Friedlander Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients J Rheumatol 21 1994 1283 1286
98. C. Nordborg, H. Johansson, and V. Petursdottir The epidemiology of biopsy-positive giant cell arteritis: special reference to changes in the age of the population Rheumatology (Oxford) 42 2003 549 552
99. E. Nordborg, and B.A. Bengtsson Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy BMJ 299 1989 549 550
100. T.C. Pearson The risk of thrombosis in essential thrombocythemia and polycythemia vera Semin Oncol 29 2002 16 21
101. D.N. Poller, Q. van Wyk, and M.J. Jeffrey The importance of skip lesions in temporal arteritis J Clin Pathol 53 2000 137 139
102. K.A. Reich, D.F. Giansiracusa, and S.L. Strongwater Neurologic manifestations of giant cell arteritis Am J Med 89 1990 67 72
103. H.L. Rittner, V. Hafner, and P.A. Klimiuk Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis J Clin Invest 103 1999 1007 1013
104. N.E. Roche, J.W. Fulbright, and A.D. Wagner Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis Arthritis Rheum 36 1993 1286 1294
105. M.G. Russo, J. Waxman, and A.A. Abdoh Correlation between infection and the onset of the giant cell (temporal) arteritis syndrome. A trigger mechanism? Arthritis Rheum 38 1995 374 380
106. K.G. Saag, R. Emkey, and T.J. Schnitzer Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group N Engl J Med 339 1998 292 299
107. C. Salvarani, F. Cantini, and L. Boiardi Polymyalgia rheumatica and giant-cell arteritis N Engl J Med 347 2002 261 271
108. C. Salvarani, S.E. Gabriel, and M.A. Gertz Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica Arthritis Rheum 37 1994 1621 1626
109. C. Salvarani, S.E. Gabriel, and W.M. O'Fallon The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern Ann Intern Med 123 1995 192 194
110. C. Salvarani, and G.G. Hunder Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study Arthritis Rheum 45 2001 140 145
111. P.A. Sandercock, C.P. Warlow, and L.N. Jones Predisposing factors for cerebral infarction: the Oxfordshire community stroke project BMJ 298 1989 75 80
112. Säve-Söderbergh J, Malmvall BE, Andersson R,, et al. Giant cell arteritis as a cause of death. Report of nine cases. JAMA 255:493-6, 1986
113. W.A. Schmidt Doppler ultrasonography in the diagnosis of giant cell arteritis Clin Exp Rheumatol 18 2000 S40 S42
114. W.A. Schmidt, H.E. Kraft, and K. Vorpahl Color duplex ultrasonography in the diagnosis of temporal arteritis N Engl J Med 337 1997 1336 1342
115. P.S. Sorensen, and I.B. Lorenzen Giant-cell arteritis, temporal arteritis and polymyalgia rheumatica. A retrospective study of 63 patients Acta Med Scand 201 1977 207 213
116. C.A. Speed, and I. Haslock Polymyalgia rheumatica, temporal arteritis and malignancy Postgrad Med J 71 1995 500 502
117. R.F. Spiera, H.J. Mitnick, and M. Kupersmith A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA) Clin Exp Rheumatol 19 2001 495 501
118. A.J. Swannell Polymyalgia rheumatica and temporal arteritis: diagnosis and management BMJ 314 1997 1329 1332
119. J.L. Tovilla-Canales Ocular manifestations of giant cell arteritis Curr Opin Ophthalmol 9 1998 73 79
120. R.E. Turbin, and M.J. Kupersmith Giant Cell Arteritis Curr Treat Options Neurol 1 1999 49 56
121. A. Uddhammar, A.L. Eriksson, and L. Nyström Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden J Rheumatol 29 2002 737 742
122. A.D. Wagner, H.C. Gérard, and T. Fresemann Detection of chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells Arthritis Rheum 43 2000 1543 1551
123. A.D. Wagner, J.J. Goronzy, and C.M. Weyand Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease J Clin Invest 94 1994 1134 1140
124. C.M. Weyand The Dunlop-Dottridge Lecture: The pathogenesis of giant cell arteritis J Rheumatol 27 2000 517 522
125. C.M. Weyand, and G.B. Bartley Giant cell arteritis: new concepts in pathogenesis and implications for management Am J Ophthalmol 123 1997 392 395
126. C.M. Weyand, J.W. Fulbright, and J.M. Evans Corticosteroid requirements in polymyalgia rheumatica Arch Intern Med 159 1999 577 584
127. C.M. Weyand, J.W. Fulbright, and G.G. Hunder Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity Arthritis Rheum 43 2000 1041 1048
128. C.M. Weyand, and J.J. Goronzy Pathogenic mechanisms in giant cell arteritis Cleve Clin J Med 69 Suppl 2 2002 SII28 SII32
129. C.M. Weyand, and J.J. Goronzy Arterial wall injury in giant cell arteritis Arthritis Rheum 42 1999 844 853
130. C.M. Weyand, and J.J. Goronzy The pathogenic role of T lymphocytes in vasculitis Sarcoidosis Vasc Diffuse Lung Dis 13 1996 217 220
131. C.M. Weyand, and J.J. Goronzy Molecular approaches toward pathologic mechanisms in giant cell arteritis and Takayasu's arteritis Curr Opin Rheumatol 7 1995 30 36
132. C.M. Weyand, and J.J. Goronzy Giant cell arteritis as an antigen-driven disease Rheum Dis Clin North Am 21 1995 1027 1039
133. C.M. Weyand, N. Tetzlaff, and J. Björnsson Disease patterns and tissue cytokine profiles in giant cell arteritis Arthritis Rheum 40 1997 19 26
134. W.S. Wilke What is the appropriate initial dose of corticosteroids to treat giant cell arteritis? Cleve Clin J Med 67 2000 546 548
135. W.S. Wilke, and G.S. Hoffman Treatment of corticosteroid-resistant giant cell arteritis Rheum Dis Clin North Am 21 1995 59 71
136. T.H. Williamson, and A. Harris Color Doppler ultrasound imaging of the eye and orbit Surv Ophthalmol 40 1996 255 267
137. C.A. Wood A memorandum book of a tenth century oculist, a translation of Tadkivate Ali Ibn Isa 1936 Northwestern University Press Chicago pp 225-6